Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

Articles published in
Anticancer Res
    May 2024
  1. WAGNER D, Karitnig R, Wienerroither V, Hau HM, et al
    Sarcopenic Obesity Promotes Recurrence in Patients Undergoing Resection for Colorectal Liver Metastases (CRLM).
    Anticancer Res. 2024;44:2177-2183.
    >> Share

  2. GON H, Komatsu S, Omiya S, Kido M, et al
    The Albumin-bilirubin Grade as Prognostic Indicator for Recurrent Hepatocellular Carcinoma Needing Repeat Liver Resection.
    Anticancer Res. 2024;44:2031-2038.
    >> Share

  3. TSUNEMATSU M, Onda S, Shirai Y, Abe K, et al
    Strategies to Perform Emergency Laparoscopic Partial Liver Resection for Ruptured Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:2171-2176.
    >> Share

  4. SEO SH, Yu JI, Park HC, Yoo GS, et al
    Proton Beam Radiotherapy as a Curative Alternative to Radiofrequency Ablation for Newly Diagnosed Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:2219-2230.
    >> Share

  5. KOIZUMI A, Komatsu S, Omiya S, Yano Y, et al
    Current Roles of Ramucirumab in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:2055-2061.
    >> Share

  6. IKUTA S, Aihara T, Kasai M, Nakajima T, et al
    Long-term Outcomes of Hepatic Resection Combined With Intraoperative Ablation Versus Hepatic Resection Alone for Multinodular Hepatocellular Carcinoma: Insights from a Single-center Study.
    Anticancer Res. 2024;44:2133-2140.
    >> Share

  7. JUNG JY, Koh SA, Lee KH
    Cold-shock Domain Protein A (CSDA) Influences Hepatocyte Growth Factor-medicated Cell Proliferation and Metastasis in Gastric Cancer Cells.
    Anticancer Res. 2024;44:1973-1981.
    >> Share

    April 2024
  8. OKUNO M, Hatano E, Tada M, Nishimura T, et al
    Surgical Intervention After Lenvatinib Treatment in Patients With Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:1727-1737.
    >> Share

  9. BEPPU T, Yamamura K, Masuda T, Miyamoto H, et al
    High-risk Patients With Colorectal Liver Metastases Assessed by the Beppu Score Can Have Excellent Survival Through Multidisciplinary Treatment Including Local Ablation.
    Anticancer Res. 2024;44:1533-1539.
    >> Share

    February 2024
  10. ACS M, Herold Z, Neumann L, Slowik P, et al
    Surgical Treatment and Outcome of Ovarian Cancer Patients With Liver Metastases: Experience of a Tertiary Hepatic and Peritoneal Surface Malignancy Center.
    Anticancer Res. 2024;44:731-741.
    >> Share

  11. KIM Y, Ajiki T, Ueda Y, Yoshida Y, et al
    Reappraisal of a Renovated Cell-free and Concentrated Ascites Reinfusion Therapy for Malignant Ascites.
    Anticancer Res. 2024;44:613-619.
    >> Share

  12. IMAOKA K, Ohira M, Shimomura M, Hattori M, et al
    Effect of Abdominal Aortic Calcification on Recurrence Following Initial Hepatectomy for Colorectal Liver Metastases.
    Anticancer Res. 2024;44:649-658.
    >> Share

    January 2024
  13. ISHIKAWA T, Yamazaki S, Sato R, Jimbo R, et al
    Efficacy of Adding Locoregional Therapy in Non-Complete Remission Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Preliminary Study.
    Anticancer Res. 2024;44:361-368.
    >> Share

  14. CHIBA N, Abe Y, Ando A, Nakagawa M, et al
    A Standardized Interrupted Parachute Suture Technique in Hepaticojejunostomy for Patients With Perihilar Cholangiocarcinoma.
    Anticancer Res. 2024;44:167-171.
    >> Share

    December 2023
  15. TOMIOKA K, Aoki T, Tashiro Y, Kusano T, et al
    Laparoscopic Anatomical Liver Resection Using Liver Mapping of Incidental Indocyanine Green Fluorescence due to Cholestasis.
    Anticancer Res. 2023;43:5583-5588.
    >> Share

  16. ZHANG XW, Mohr J, Halama N, Koschny R, et al
    Analysis of an Unselected Patient Cohort With Advanced Colorectal Carcinoma from a Maximum Care Center.
    Anticancer Res. 2023;43:5589-5596.
    >> Share

    November 2023
  17. SHIOZAKI A, Kurashima K, Kudou M, Shimizu H, et al
    Cancer Stem Cells of Hepatocellular Carcinoma Are Suppressed by the Voltage-gated Calcium Channel Inhibitor Amlodipine.
    Anticancer Res. 2023;43:4855-4864.
    >> Share

  18. SANO A, Sohda M, Hosoi N, Tateno K, et al
    Importance of Progression-free Survival in Second-line Chemotherapy in Patients With Advanced or Recurrent Gastric Cancer.
    Anticancer Res. 2023;43:5205-5213.
    >> Share

  19. OSHITA KO, Kobayashi T, Tadokoro T, Namba Y, et al
    Outcomes and Prognostic Analysis of Surgical Resection for Oligometastasis from Hepatocellular Carcinoma.
    Anticancer Res. 2023;43:5189-5196.
    >> Share

    October 2023
  20. KOBAYASHI K, Nagai H, Matsui T, Matsuda T, et al
    Importance of Atezolizumab Plus Bevacizumab Combination Treatment as First-line Therapy for Immunological Changes in Patients With Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2023;43:4601-4609.
    >> Share

  21. MUTO H, Kuzuya T, Kawabe N, Ohno E, et al
    Clinical Outcomes With Lenvatinib in Patients Previously Treated With Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2023;43:4673-4682.
    >> Share

  22. GARRETT C, Cristaudo A, Barat S, Morris DL, et al
    Increased Incidence of Liver Metastases in Colorectal Versus Appendiceal Adenocarcinoma Peritonectomy Patients Despite Equivocal Survival.
    Anticancer Res. 2023;43:4657-4662.
    >> Share

  23. YANG JD, Yueh PF, Liao TL, Chen YT, et al
    Unlocking Synergistic Potential: Enhancing Regorafenib Efficacy in Hepatocellular Carcinoma Through Combination Therapy With 18beta-Glycyrrhetinic Acid.
    Anticancer Res. 2023;43:4403-4412.
    >> Share

  24. WANG CC, Fan WL, Liu TT, Pang ST, et al
    Impact of Genomic Alterations on the Clinical Outcome of Patients With Hepatitis B-related Hepatocellular Carcinoma Receiving Curative Surgery: A Retrospective Cohort Study.
    Anticancer Res. 2023;43:4709-4722.
    >> Share

  25. LEE YJ, Kim KC, Lee JM, Lim JM, et al
    Development of Polyethylene Glycol-based Hydrogels Optimized for In Vitro 3D Culture of HepG2 Hepatocarcinoma Cells.
    Anticancer Res. 2023;43:4373-4377.
    >> Share

  26. YAMAMURA K, Beppu T, Miyata T, Mima K, et al
    Surgery for Hepatocellular Carcinoma With Macroscopic Vascular Invasion in the Era of Modern Molecular Therapy.
    Anticancer Res. 2023;43:4285-4293.
    >> Share

    September 2023
  27. SHINZATO R, Nishie A, Tamaki T, Wada N, et al
    Prediction of Early-stage Liver Fibrosis Using FDG-PET/CT.
    Anticancer Res. 2023;43:4221-4227.
    >> Share

  28. MINOJI T, Takahashi H, Watabe T, Ishikawa S, et al
    The Clinical Potential of FBPA-PET/CT Imaging for Colorectal Cancer and its Liver Metastases Expressing LAT1.
    Anticancer Res. 2023;43:3913-3921.
    >> Share

  29. PSILOPATIS I, Garmpis N, Garmpi A, Vrettou K, et al
    Liver Cancer and Pregnancy: A Review of the Literature.
    Anticancer Res. 2023;43:3861-3869.
    >> Share

  30. HU B, Wei LU, Liang H, Su M, et al
    Correlation Between Serum ESPL1 and Hepatitis B Virus-related Hepatocellular Carcinoma Histological Grade: A Chinese Single-center Case-control Study.
    Anticancer Res. 2023;43:3997-4005.
    >> Share

    August 2023
  31. WU LW, Hu X
    SSNA1 Promotes Hepatocellular Carcinoma Metastasis Via STAT3/EMT Induction.
    Anticancer Res. 2023;43:3479-3486.
    >> Share

  32. KATAGIRI M, Sudo T, Tounann T, Kakuma T, et al
    Development of an Algorithm to Predict Recurrences After Resection of Liver Metastases in Patients With Metastatic Colorectal Cancer.
    Anticancer Res. 2023;43:3807-3816.
    >> Share

  33. HIRAKAWA H, Sakai H, Kanno H, Goto Y, et al
    Significance of Desmoplastic Histopathological Growth Pattern for Colorectal Liver Metastases Treated With Preoperative Chemotherapy.
    Anticancer Res. 2023;43:3727-3733.
    >> Share

  34. ISHIKAWA T, Imai M, Sato R, Jimbo R, et al
    Prognostic Value of TACE With Irinotecan-loaded Drug-eluting Beads (DEBIRI) in Patients With Liver Metastases from Unresectable Colorectal Cancer.
    Anticancer Res. 2023;43:3647-3651.
    >> Share

    July 2023
  35. CHEN YH, Tsai CH, Chen YY, Wang CC, et al
    The Efficacy and Safety of Ramucirumab in Heavily Pretreated Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2023;43:3203-3212.
    >> Share

  36. TAN CQY, Ho A, Robinson HA, Huang L, et al
    A Systematic Review of Microwave Ablation for Colorectal Pulmonary Metastases.
    Anticancer Res. 2023;43:2899-2907.
    >> Share

    May 2023
  37. BIMBATTI D, Cavasin N, Galuppini F, Rago A, et al
    Liver Metastases of Unknown Primary Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors: A Case Report and Literature Review.
    Anticancer Res. 2023;43:2359-2365.
    >> Share

  38. ARAKI K, Harimoto N, Watanabe A, Tsukagoshi M, et al
    Laparoscopic Liver Resection Procedure Attenuates Organ-space Surgical Site Infection Compared With Open Procedure: A Propensity Score-matched Analysis.
    Anticancer Res. 2023;43:2273-2280.
    >> Share

    April 2023
  39. YUGAWA K, Maeda T, Nagata S, Sakai A, et al
    Prognostic Impact of a Novel Albumin-Platelet Index as Selection Criterion for Hepatic Resection in Intermediate Stage Hepatocellular Carcinoma.
    Anticancer Res. 2023;43:1835-1842.
    >> Share

  40. YAMAMURA K, Beppu T, Kinoshita K, Matsumura K, et al
    A Laparoscopically Treated Case of Peritoneal Dissemination Mimicking Liver Metastases from Distal Cholangiocarcinoma Four Years After the Initial Pancreaticoduodenectomy.
    Anticancer Res. 2023;43:1863-1867.
    >> Share

  41. SHIOZAKI H, Furukawa K, Haruki K, Matsumoto M, et al
    A Multidisciplinary Treatment Strategy With Conversion Surgery for Hepatocellular Carcinoma.
    Anticancer Res. 2023;43:1761-1766.
    >> Share

  42. TAKISHIMA T, Haruki K, Taniai T, Furukawa K, et al
    The Japanese 5-5-500 Rule Predicts Prognosis of Hepatocellular Carcinoma After Hepatic Resection.
    Anticancer Res. 2023;43:1623-1629.
    >> Share

  43. PERSANO M, Rimini M, Tada T, Suda G, et al
    Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index.
    Anticancer Res. 2023;43:1599-1610.
    >> Share

  44. MANO Y, Abe K, Takahashi M, Higurashi T, et al
    Optimal Administration of Glycyrrhizin Avoids Pharmacokinetic Interactions With High-dose Methotrexate and Exerts a Hepatoprotective Effect.
    Anticancer Res. 2023;43:1493-1501.
    >> Share

    March 2023
  45. OGAWA K, Chiba T, Nakamura M, Arai J, et al
    Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 Inhibitors.
    Anticancer Res. 2023;43:1043-1052.
    >> Share

  46. HUANG YH, Yeh CT
    Anticancer Effects of Antidepressants in Hepatocellular Carcinoma Cells.
    Anticancer Res. 2023;43:1201-1206.
    >> Share

  47. CHEN YH, Chen YY, Wang JH, Hung CH, et al
    Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients.
    Anticancer Res. 2023;43:1377-1384.
    >> Share

  48. ENOMOTO D, Yamamoto K, Matsumoto Y, Morioka A, et al
    ALBI Grade Is a Predictive Factor of Lenvatinib Treatment Discontinuation due to Adverse Events in Hepatocellular Carcinoma.
    Anticancer Res. 2023;43:1317-1323.
    >> Share

  49. LI JR, Wang SS, Lu K, Chen CS, et al
    First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
    Anticancer Res. 2023;43:1331-1339.
    >> Share

  50. CHENG JY, Huang BS, Chen YY, Wang CC, et al
    Combination of Lenvatinib and Proton Beam Therapy in the Management of Patients With Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2023;43:1361-1371.
    >> Share

    February 2023
  51. XU M, Tsunedomi R, Kiyotani K, Tomochika S, et al
    Anti-VEGF and Anti-EGFR Antibody Therapy on T-Cell Infiltration and TCR Variation in Metastatic Colorectal Cancer.
    Anticancer Res. 2023;43:613-620.
    >> Share

  52. KUMAMOTO T, Takeda K, Matsuyama R, Sawada YU, et al
    Glasgow Prognostic Score Predicts Survival and Recurrence Pattern in Patients With Hepatocellular Carcinoma After Hepatectomy.
    Anticancer Res. 2023;43:875-882.
    >> Share

  53. MARROCCO GA, Silletta M, Bianco V, Mondera F, et al
    Lenvatinib Versus Sorafenib in Advanced Hepatic Cell Carcinoma: A Double Center Retrospective Analysis.
    Anticancer Res. 2023;43:755-763.
    >> Share

  54. NAKAGAWA D, Komatsu S, Yano Y, Kido M, et al
    Outcomes of the Sequential Treatment of Unresectable Hepatocellular Carcinoma Using Lenvatinib.
    Anticancer Res. 2023;43:911-918.
    >> Share

  55. MIYATA T, Sugi K, Horino T, Ono A, et al
    Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture.
    Anticancer Res. 2023;43:943-947.
    >> Share

    January 2023
  56. AKINO Y, Shiomi H, Higashinaka N, Kouno T, et al
    Evaluation of Lung and Liver Tumor Dose Coverage Treated With the CyberKnife Synchrony System With Consideration of Measured Tracking Errors.
    Anticancer Res. 2023;43:231-238.
    >> Share

  57. KANG Y, Han M, Kim M, Hwang HJ, et al
    Cytotoxicity of Human Hepatic Intrasinusoidal Gamma/Delta T Cells Depends on Phospho-antigen and NK Receptor Signaling.
    Anticancer Res. 2023;43:63-73.
    >> Share

  58. ARAKI K, Harimoto N, Shibuya K, Watanabe A, et al
    Significance of Skeletal Muscle Loss in Liver Hypertrophy in Patients Undergoing Portal Vein Embolization Before Major Hepatectomy: Assessment With Body Composition and Nutritional Indicators.
    Anticancer Res. 2023;43:209-216.
    >> Share

    December 2022
  59. TAJIRI K, Tokimitsu Y, Kawai K, Motofuji Y, et al
    Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study.
    Anticancer Res. 2022;42:6007-6018.
    >> Share

  60. IMAOKA Y, Ohira M, Sato K, Imaoka K, et al
    Impact of Abdominal Aortic Calcification After Major Hepatobiliary Pancreatic Surgery: A Retrospective Cohort Study.
    Anticancer Res. 2022;42:5983-5989.
    >> Share

  61. SHIBANO M, Takahashi K, Takahashi M, Uchida-Kobayashi S, et al
    Prognostic Nutrition Index as an Indicator of Therapeutic Response to Lenvatinib Therapy in Hepatocellular Carcinoma.
    Anticancer Res. 2022;42:6019-6026.
    >> Share

  62. SEO S, Hatano E, Kanai M, Ogawa K, et al
    Prospective Observational Study of Sorafenib in Hepatocellular Carcinoma Patients With Very High Risk of Recurrence After Surgery.
    Anticancer Res. 2022;42:6127-6134.
    >> Share

  63. TANIGUCHI A, Kittaka N, Kanaoka H, Nakajima S, et al
    Risk of Abemaciclib-induced Liver Injury in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer: A Retrospective Analysis.
    Anticancer Res. 2022;42:6027-6035.
    >> Share

    November 2022
  64. TAKEDA S, Namisaki T, Tsuji Y, Fujimoto Y, et al
    Initial Experience With Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: A Real-world Retrospective Study.
    Anticancer Res. 2022;42:5465-5473.
    >> Share

  65. TAKEDA K, Kikuchi Y, Sawada YU, Kumamoto T, et al
    Efficacy of Adjuvant Chemotherapy Following Curative Resection of Colorectal Cancer Liver Metastases.
    Anticancer Res. 2022;42:5497-5505.
    >> Share

  66. YUEH TC, Tsao HY, Chien WC, Tsai CW, et al
    The Contribution of Matrix Metalloproteinase-7 Promoter Genotypes to Hepatocellular Carcinoma Susceptibility.
    Anticancer Res. 2022;42:5275-5282.
    >> Share

  67. HUANG G, Howard LN, Alonsozana E, Sill D, et al
    Molecular Characteristics and Immunogenomic Profiling of Cholangioblastic Variant of Intrahepatic Cholangiocarcinoma in a 68-year-old Patient.
    Anticancer Res. 2022;42:5475-5478.
    >> Share

  68. SASAKI T, Shigeta K, Kitahara S, Suzuki Y, et al
    Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment.
    Anticancer Res. 2022;42:5205-5215.
    >> Share

  69. SCHMITZ V, Bauerschmitz G, Gallwas J, Grundker C, et al
    Suppression of G Protein-coupled Estrogen Receptor 1 (GPER1) Enhances the Anti-invasive Efficacy of Selective ERbeta Agonists.
    Anticancer Res. 2022;42:5187-5194.
    >> Share

  70. KIM SH, Song SE, Baik H, Hur DY, et al
    15-Prostaglandin Dehydrogenase Inhibition Enhances Colon Cancer Metastasis by Up-regulation of Epithelial-to-Mesenchymal Transition Genes.
    Anticancer Res. 2022;42:5385-5396.
    >> Share

  71. KOMATSU S, Yano Y, Kido M, Kuramitsu K, et al
    Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma.
    Anticancer Res. 2022;42:5479-5486.
    >> Share

  72. YAMAMURA K, Beppu T, Inoue K, Matsumura K, et al
    Vater Papilla-preserving Strategy for Advanced Hepatocellular Carcinoma With Excessive Bile Duct Tumor Thrombus.
    Anticancer Res. 2022;42:5663-5670.
    >> Share

    October 2022
  73. HUANG J, Xi Q, Xiong J, Peng H, et al
    Micro RNA miR-1303 Promotion of Proliferation, Migration and Invasion of Human Liver Cancer Cells Is Enhanced by Low Talin 1 (TLN1) Expression.
    Anticancer Res. 2022;42:4715-4725.
    >> Share

  74. NAGATA K, Sasaki R, Iwatsu S, Fukushima M, et al
    Long-term Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma.
    Anticancer Res. 2022;42:5001-5007.
    >> Share

  75. FUJIMOTO Y, Namisaki T, Takeda S, Murata K, et al
    Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Lenvatinib.
    Anticancer Res. 2022;42:4895-4905.
    >> Share

  76. HANAKI T, Goto K, Morimoto M, Murakami Y, et al
    Surgical Administration of Indocyanine Green in Hepatectomy for Improved Bile Leakage Detection.
    Anticancer Res. 2022;42:4787-4793.
    >> Share

  77. UTSUMI M, Inagaki M, Kitada K, Tokunaga N, et al
    Lymphocyte-to-C-Reactive Protein Ratio Predicts Prognosis in Patients With Colorectal Liver Metastases Post-hepatic Resection: A Retrospective Study.
    Anticancer Res. 2022;42:4963-4971.
    >> Share

    September 2022
  78. NANASHIMA A, Tanoue Y, Hiyoshi M, Imamura N, et al
    Prognostic Value of Repeat Hepatectomy for Hepatocellular Carcinoma Patients.
    Anticancer Res. 2022;42:4553-4561.
    >> Share

  79. CHEN CT, Hsu CH, Cheng AL, Shao YY, et al
    Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study.
    Anticancer Res. 2022;42:4461-4470.
    >> Share

  80. TAN C, Fisher OM, Huang L, Alzahrani N, et al
    Comparison of Microwave and Radiofrequency Ablation in the Treatment of Pulmonary Metastasis of Colorectal Cancer.
    Anticancer Res. 2022;42:4563-4571.
    >> Share

  81. CRISTAUDO AT, Jennings SB, Morris DL
    Comparison of Proportion of Elevated Carcinoembryonic Antigen Levels in Patients With Appendiceal and Colorectal Adenocarcinoma: A Systematic Review and Meta-analysis.
    Anticancer Res. 2022;42:4217-4235.
    >> Share

    August 2022
  82. SASAKI S, Nomura Y, Sudo T, Sakai H, et al
    Hematogenous Dissemination of Tumor Cells in Hepatocellular Carcinoma: Comparing Anterior and Non-anterior Approach Hepatectomy.
    Anticancer Res. 2022;42:4129-4137.
    >> Share

  83. IMAI N, Ishigami M, Oie Y, Kumagai M, et al
    Effectiveness of Porous Glass Membrane Pumping Emulsification Device in Transarterial Chemoembolization for Solitary Hepatocellular Carcinoma.
    Anticancer Res. 2022;42:3947-3951.
    >> Share

  84. SHIRAHAMA N, Goto Y, Sakai H, Fukutomi S, et al
    Liberal Application of Portal Vein Embolization for Right Hepatectomy Against Hepatocellular Carcinoma: Strategy to Achieve Zero Mortality for a Damaged Liver.
    Anticancer Res. 2022;42:4089-4095.
    >> Share

  85. WAKAME K, Sato K, Kasai M, Kikuchi E, et al
    Oral Administration of Mulberry (Morus alba L.) Leaf Powder Prevents the Development of Hepatocellular Carcinoma in Stelic Animal Model (STAM) Mice.
    Anticancer Res. 2022;42:4055-4062.
    >> Share

  86. JU M, Aoyama T, Komori K, Tamagawa H, et al
    The Albumin-Bilirubin Score Is a Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment.
    Anticancer Res. 2022;42:3929-3935.
    >> Share

  87. NOMURA Y, Akiba J, Yano H, Akagi Y, et al
    Fatty Liver Does Not Increase the Risk of Postoperative Liver Damage Following Hepatectomy.
    Anticancer Res. 2022;42:4159-4164.
    >> Share

    July 2022
  88. KANG BY, Kim SM, Hur W, Roh PR, et al
    Enhanced Tumoricidal Immune Responses by Transarterial Chemotherapy Using Novel Nanocomplexes in a Rat Liver Cancer Model.
    Anticancer Res. 2022;42:3463-3473.
    >> Share

  89. NAKASEKO Y, Furukawa K, Haruki K, Onda S, et al
    Standardized and Feasible Laparoscopic Approach for Tumors Located in the Caudate Lobe.
    Anticancer Res. 2022;42:3621-3625.
    >> Share

  90. HUDSON JM, Singh S, Milot L, Patel C, et al
    Dynamic Contrast-enhanced CT to Evaluate Early Response in Neuroendocrine Liver Metastases Treated With Everolimus and Radiation.
    Anticancer Res. 2022;42:3523-3527.
    >> Share

    June 2022
  91. MATSUMURA K, Yamamura K, Oda E, Akahoshi S, et al
    Successful Treatment of Intrahepatic Cholangiocarcinoma With Liver/Lung Metastasis and Peritoneal Dissemination After Liver Resection.
    Anticancer Res. 2022;42:3209-3215.
    >> Share

  92. HIDAKA M, Hara T, Soyama A, Sasaki R, et al
    The Outcome of Conversion Liver Resection Surgery by Lenvatinib Treatment: A Single Center Experience.
    Anticancer Res. 2022;42:3049-3054.
    >> Share

    May 2022
  93. HSIEH CH, Yeh CT, Huang YH, Lai MW, et al
    Circulating Tumor Cells Derived from Advanced Hepatocellular Carcinoma Rapidly Develop Resistance to Cytotoxic Chemotherapy.
    Anticancer Res. 2022;42:2479-2486.
    >> Share

  94. KUMAMOTO T, Matsuyama R, Takeda K, Sawada YU, et al
    Surgical Indications for Huge Hepatocellular Carcinoma.
    Anticancer Res. 2022;42:2573-2581.
    >> Share

  95. YANG CJ, Wu MH, Tsai JJ, Hsu FT, et al
    Inactivation of AKT/ERK Signaling and Induction of Apoptosis Are Associated With Amentoflavone Sensitization of Hepatocellular Carcinoma to Lenvatinib.
    Anticancer Res. 2022;42:2495-2505.
    >> Share

    April 2022
  96. KUZUYA T, Kawabe N, Hashimoto S, Funasaka K, et al
    Clinical Outcomes of Ramucirumab as Post-treatment Following Atezolizumab/Bevacizumab Combination Therapy in Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2022;42:1905-1910.
    >> Share

  97. HANAKI T, Sunaguchi T, Goto K, Morimoto M, et al
    The Significance of Surgical Intervention for Metasynchronous Liver Metastasis in Gastric Cancer: A Single-centre Analysis.
    Anticancer Res. 2022;42:2177-2184.
    >> Share

  98. TOMITA K, Chiba N, Ochiai S, Gunji T, et al
    Prognostic Impact of N2 of the Primary Tumour in Surgical Resection for Colorectal Liver Metastases.
    Anticancer Res. 2022;42:1997-2001.
    >> Share

    March 2022
  99. KOMATSU S, Yano Y, Fujishima Y, Ishida J, et al
    Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2022;42:1403-1412.
    >> Share

  100. HAMAYA S, Fujihara S, Iwama H, Fujita K, et al
    Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells.
    Anticancer Res. 2022;42:1263-1275.
    >> Share

  101. MATSUMURA K, Yamamura K, Miyamoto H, Hara Y, et al
    Highly Advanced Colorectal Liver Metastases Successfully Treated With Fluorouracil Plus Leucovorin Monotherapy and Microwave Ablation.
    Anticancer Res. 2022;42:1645-1651.
    >> Share

  102. BARAK V, Kalickman I, Pe'er J
    sIL-2R- an Immuno-biomarker for Prediction of Metastases in Uveal Melanoma.
    Anticancer Res. 2022;42:1447-1453.
    >> Share

  103. TASHIRO Y, Aoki T, Hirai T, Koizumi T, et al
    Indocyanine Green Labeling of Tumors in the Liver Recurring After Radiofrequency Ablation Enables Complete Resection by Fluorescence-guided Surgery.
    Anticancer Res. 2022;42:1345-1350.
    >> Share

    February 2022
  104. ICHIDA A, Akamatsu N, Nagata R, Mihara Y, et al
    Efficacy and Safety of Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Report of Two Cases.
    Anticancer Res. 2022;42:1161-1167.
    >> Share

  105. ABE K, Maeda-Minami A, Ishizu T, Iwata S, et al
    Risk Factors for Hepatic Toxicity of High-dose Methotrexate in Patients With Osteosarcoma.
    Anticancer Res. 2022;42:1043-1050.
    >> Share

  106. FUJITA N, Handa A, Park JM
    Peritumoral Hyperintensity at Hepatobiliary Phase Gadoxetic Acid-enhanced MRI in Hepatic Neuroendocrine Tumors.
    Anticancer Res. 2022;42:911-917.
    >> Share

  107. JANG WI, Kim MS, Jeong JH, Kim W, et al
    Enhancement of Radiation Response Associated With Metformin in Hepatocellular Carcinoma: Preclinical Animal and Clinical Cohort Study.
    Anticancer Res. 2022;42:867-876.
    >> Share

  108. ZIOGAS IA, Schmitz R, Moris D, Vatsaas CJ, et al
    The Role of Surgery for Pancreatic Neuroendocrine Tumors.
    Anticancer Res. 2022;42:629-639.
    >> Share

    January 2022
  109. YAMAMURA K, Beppu T, Miyata T, Okabe H, et al
    Conversion Surgery for Hepatocellular Carcinoma Following Molecular Therapy.
    Anticancer Res. 2022;42:35-44.
    >> Share

  110. AURELLO P, Minervini A, Pace M, D'Angelo F, et al
    The Role of Surgery in the Treatment of Metachronous Liver Metastasis from Gastric Cancer: A Systematic Review.
    Anticancer Res. 2022;42:25-33.
    >> Share

  111. INOUE KI, Yamagishi H, Jojima T, Inoue T, et al
    Development of Non-alcoholic Steatohepatitis and Nodular Regenerative Hyperplasia in C57BL/6J Mice Fed a Fructose-containing Western Diet.
    Anticancer Res. 2022;42:609-617.
    >> Share

  112. JUNG JY, Koh SA, Lee KH, Kim JR, et al
    14-3-3 Sigma Protein Contributes to Hepatocyte Growth Factor-mediated Cell Proliferation and Invasion via Matrix Metalloproteinase-1 Regulation in Human Gastric Cancer.
    Anticancer Res. 2022;42:519-530.
    >> Share

  113. MIZUOCHI S, Akiba J, Kondo R, Kusano H, et al
    Clinicopathological Analysis of Non-B Non-C Hepatocellular Carcinoma Focusing on Cellular Proliferation.
    Anticancer Res. 2022;42:449-457.
    >> Share

  114. HARIMOTO N, Itoh S, Yamanaka T, Hagiwara K, et al
    Mac-2 Binding Protein Glycosylation Isomer as a Prognostic Marker for Hepatocellular Carcinoma With Sustained Virological Response.
    Anticancer Res. 2022;42:245-251.
    >> Share

  115. SHIMOZATO N, Namisaki T, Okano A, Ohana M, et al
    Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan.
    Anticancer Res. 2022;42:173-183.
    >> Share

    November 2021
  116. IMAI N, Yokoyama S, Yamamoto K, Ito T, et al
    Safety and Efficacy of Glass Membrane Pumping Emulsification Device in Transarterial Chemoembolization for Hepatocellular Carcinoma: First Clinical Outcomes.
    Anticancer Res. 2021;41:5817-5820.
    >> Share

  117. OMIYA S, Komatsu S, Kido M, Kuramitsu K, et al
    Impact of Sarcopenia as a Prognostic Factor on Reductive Hepatectomy for Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:5775-5783.
    >> Share

  118. ADACHI Y, Yamamura K, Yumoto S, Higashi T, et al
    Far-advanced Colorectal Liver Metastases Successfully Managed With Modified ALPPS and Radiofrequency Ablation in Combination With Chemotherapy.
    Anticancer Res. 2021;41:5855-5861.
    >> Share

  119. FURUKAWA K, Onda S, Taniai T, Hamura R, et al
    Risk Factors and Overcoming Strategies of Surgical Site Infection After Hepatectomy for Colorectal Liver Metastases.
    Anticancer Res. 2021;41:5651-5656.
    >> Share

  120. MASATSUNE S, Kimura K, Kashiwagi S, En W, et al
    Impact of Intraoperative Blood Loss and Blood Transfusion on the Prognosis of Colorectal Liver Metastasis Following Curative Resection.
    Anticancer Res. 2021;41:5617-5623.
    >> Share

  121. TAGO T, Katsumata K, Udou R, Kasahara K, et al
    Significance of Radiofrequency Ablation for Unresectable Colorectal Cancer With Liver Metastases.
    Anticancer Res. 2021;41:5539-5547.
    >> Share

  122. TSOCHANTARIDIS I, Voulgaridou GP, Giatromanolaki A, Koukourakis MI, et al
    Profiling of Aldehyde Dehydrogenase Isoforms in In Vitro Formed Tumorspheres.
    Anticancer Res. 2021;41:5481-5488.
    >> Share

    October 2021
  123. ODA E, Yamamura K, Hara Y, Matsumura K, et al
    Intrahepatic Cholangiocarcinoma Coexisting With Multiple Bile Duct Adenoma Treated as Liver Metastasis from a Pancreatic Neuroendocrine Tumor.
    Anticancer Res. 2021;41:5249-5254.
    >> Share

  124. KIM M, Kim HC, Chung JW
    Chemoembolization for Hepatocellular Carcinoma in Patients With Inferior Vena Caval/Right Atrial Tumor Thrombi Without Hepatic Vein Invasion.
    Anticancer Res. 2021;41:5241-5247.
    >> Share

  125. MOON H, Park H, Ro SW
    c-Myc-driven Hepatocarcinogenesis.
    Anticancer Res. 2021;41:4937-4946.
    >> Share

    September 2021
  126. KOMATSU S, Yano Y, Kido M, Kuramitsu K, et al
    Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:4555-4562.
    >> Share

  127. OKAMOTO H, Shiba S, Iino H, Sudoh M, et al
    Tumor Vascular Microenvironment of Colorectal Hepatic Metastasis and Chemotherapy Response.
    Anticancer Res. 2021;41:4505-4513.
    >> Share

  128. TSUNEMATSU M, Onda S, Yanagaki M, Okui N, et al
    How to Perform Curative Laparoscopic Hepatectomy for Intraoperatively Unidentified Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:4411-4416.
    >> Share

  129. TOKUDA K, Morine Y, Miyazaki K, Yamada S, et al
    Frailty Can Predict Prognosis After Hepatectomy in Patients With Colorectal Liver Metastasis.
    Anticancer Res. 2021;41:4637-4644.
    >> Share

    August 2021
  130. YAMANAKA M, Hayashi M, Yamada S, Sonohara F, et al
    A Possible Definition of Oligometastasis in Pancreatic Cancer and Associated Survival Outcomes.
    Anticancer Res. 2021;41:3933-3940.
    >> Share

  131. OURA K, Aoki T, Tashiro Y, Matsuda K, et al
    Indocyanine Green Fluorescence Image-guided Laparoscopic Hepatectomy Enabled Resection of a Tumor Invisible With Ultrasonography.
    Anticancer Res. 2021;41:3867-3869.
    >> Share

    July 2021
  132. KUBO H, Ikoma H, Yamamoto Y, Morimura R, et al
    Therapeutic Strategy of Colorectal Liver Metastasis Using Modified-JHBPS Nomogram.
    Anticancer Res. 2021;41:3657-3665.
    >> Share

  133. VIEIRA JF, Peixoto AP, Murta EFC, Michelin MA, et al
    Prophylactic Dendritic Cell Vaccination in Experimental Breast Cancer Controls Immunity and Hepatic Metastases.
    Anticancer Res. 2021;41:3419-3427.
    >> Share

    June 2021
  134. AU KY, Chan KK, Lo RC
    A Clinicopathological Study of Young-onset Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:2933-2944.
    >> Share

    May 2021
  135. YAMAMURA K, Beppu T, Oda E, Sato N, et al
    Hepatic Inflammatory Pseudotumor Mimicking Malignant Tumor With Rare Onset of Intra-abdominal Hemorrhage.
    Anticancer Res. 2021;41:2727-2732.
    >> Share

  136. KIM HC, Choi JW, Lee M, Kim YJ, et al
    Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Virtual Tumor Absorbed Dose as a Predictor of Complete Response.
    Anticancer Res. 2021;41:2625-2635.
    >> Share

  137. YAMAMOTO T, Imai N, Yamamoto K, Ito T, et al
    Tolerability of Molecular-targeted Agents for Hepatocellular Carcinoma Treatment in Haemophiliacs.
    Anticancer Res. 2021;41:2569-2573.
    >> Share

  138. ISHIGAMI I, Shuwari N, Kaminade T, Mizuguchi H, et al
    A TGFbeta Signaling Inhibitor, SB431542, Inhibits Reovirus-mediated Lysis of Human Hepatocellular Carcinoma Cells in a TGFbeta-independent Manner.
    Anticancer Res. 2021;41:2431-2440.
    >> Share

  139. SHIBUTANI M, Kimura K, Kashiwagi S, Wang EN, et al
    Elevated Postoperative Levels of Serum C-reactive Protein Are Associated With Shorter Long-term Survival After Resection of Colorectal Liver Metastases, Regardless of the Occurrence of Infectious Complications.
    Anticancer Res. 2021;41:2605-2610.
    >> Share

  140. NISHIKAWA H, Fukunishi S, Asai A, Nishiguchi S, et al
    Obesity and Liver Cancer in Japan: A Comprehensive Review.
    Anticancer Res. 2021;41:2227-2237.
    >> Share

    April 2021
  141. MAESAKA K, Sakamori R, Yamada R, Tahata Y, et al
    Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:2187-2192.
    >> Share

  142. FURUKAWA K, Haruki K, Yasuda J, Onda S, et al
    Strategies to Perform Curative Laparoscopic Repeat Hepatectomy for Recurrent Liver Tumors After Open Right Lobectomy.
    Anticancer Res. 2021;41:2171-2175.
    >> Share

  143. SASAKI R, Fukushima M, Haraguchi M, Miuma S, et al
    Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib.
    Anticancer Res. 2021;41:2025-2032.
    >> Share

  144. SHAO C, Shao PP, Chen WT, Lin CC, et al
    Direct-acting Antiviral Therapy Improves the Outcome of Chronic Hepatitis C/intermediate-stage B Hepatocellular Carcinoma Patients.
    Anticancer Res. 2021;41:2007-2016.
    >> Share

  145. YASUHARA Y, Komatsu S, Kuramitsu K, Kido M, et al
    Feasibility of Reductive Hepatectomy in Patients With BCLC B and C Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:1975-1983.
    >> Share

  146. LEE GW, Hur W, Kim JH, Park DJ, et al
    Nardostachys jatamansi Root Extract Attenuates Tumor Progression in Hepatocellular Carcinoma via Inhibition of ERK/STAT3 Pathways.
    Anticancer Res. 2021;41:1883-1893.
    >> Share

  147. NISHINO H, Okuno M, Seo S, Toda R, et al
    Sinusoidal Obstruction Syndrome Promotes Liver Metastatic Seeding of Colorectal Cancer Cells in a Rat Model.
    Anticancer Res. 2021;41:1803-1810.
    >> Share

  148. SHIBA S, Shibuya K, Okamoto M, Okano N, et al
    Carbon-ion Radiotherapy for Oligometastatic Colorectal Cancer in the Liver or Lung.
    Anticancer Res. 2021;41:1997-2005.
    >> Share

    March 2021
  149. NAKANISHI Y, Hirota S, Hojo Y, Nakamura T, et al
    Pathological Complete Remission of Liver Metastases Correlates With Elimination of Tumor-infiltrating Tregs in Gastric Cancer.
    Anticancer Res. 2021;41:1571-1577.
    >> Share

  150. HIROSE Y, Sakata J, Kobayashi T, Miura K, et al
    NQO1 as a Marker of Chemosensitivity and Prognosis for Colorectal Liver Metastasis.
    Anticancer Res. 2021;41:1563-1570.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016